Prospective Exploratory Study of Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Postoperative Recurrence of Pancreatic Cancer
Latest Information Update: 04 Sep 2023
At a glance
- Drugs Tislelizumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer; Postoperative complications
- Focus Therapeutic Use
- 31 Aug 2023 Planned primary completion date changed from 20 Nov 2022 to 20 Nov 2023.
- 31 May 2021 New trial record